ZFIN Image: Evason et al., 2015, Fig. S6

Image

Figure Caption

Fig. S6 Small molecule screen for compounds that suppress larval liver enlargement caused by activated β-catenin.

Transgenic zebrafish expressing activated β-catenin (Tg(fabp10a:pt-β-cat, cryaa:Venus)) were crossed to zebrafish expressing liver-specific GFP (Tg(fabp10a:EGFP). At 3 days old, larvae with green livers (fabp10a:EGFP+) were selected for drug treatment. Zebrafish with activated β-catenin, identified by their fluorescent eyes, were treated in parallel to control zebrafish without activated β-catenin. Three zebrafish were placed in each well, and 4 wells were tested for each experimental compound and vehicle (DMSO) control. Liver size was scored qualitatively 3 days post treatment (dpt). Drugs that decreased average liver size of Tg(fabp10a:pt-β-cat); Tg(fabp10a:EGFP) zebrafish in both wells compared to DMSO controls without causing toxicity/death in any wells were considered potential hit compounds.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ PLoS Genet.